Subretinal Implant for Geographic Atrophy AMD Vision Restoration
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.This translates to a hazard ratio...
- This finding is especially relevant for individuals with pre-existing cardiovascular disease, including those with a history of heart attack, stroke, or peripheral artery disease.
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated notable weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.This translates to a hazard ratio of 1.33, indicating a 33% increased risk. Though, it’s crucial to note that the trial also showed a significant reduction in the development of type 2 diabetes among participants.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| MACE (Heart Attack, Stroke, Cardiovascular Death) | 6.5 | 4.9 | 1.33 |
| New-Onset Type 2 Diabetes | 15.0 | 25.3 | 0.57 |
Who is Affected? Understanding the Patient population
This finding is especially relevant for individuals with pre-existing cardiovascular disease, including those with a history of heart attack, stroke, or peripheral artery disease. The SELECT trial specifically enrolled participants with established cardiovascular disease, meaning the increased risk wasn’t observed in a generally healthy obese population. It’s crucial to emphasize that this doesn’t necessarily mean Ozempic is dangerous for *everyone* but highlights the need for careful risk-benefit assessment.
The trial included participants with a Body Mass Index (BMI) of 27 or higher, and at least one cardiovascular event within the past five years. The average age of participants was 61.3 years, and approximately half were women.
Why Does This Matter? The Implications for Weight Loss Medications
The widespread use of semaglutide and other GLP-1 receptor agonists for weight loss has been rapidly increasing. These medications have been lauded for their efficacy in promoting weight reduction, but the SELECT trial introduces a critical caveat.The findings underscore the importance of considering the cardiovascular health of patients before initiating treatment and implementing appropriate monitoring strategies.
Timeline of Events and ongoing Research
August 17,2023: Results of the SELECT trial are publicly released and published ahead of print in the New England